Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465424 | 0.93 | — | — | |
| SCHEMBL5455706 | 0.88 | ALDH1A1 (0.33) | ALDH1A1HCAR2 | |
| SCHEMBL5466058 | 0.87 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL5458679 | 0.85 | ALDH1A1 (0.31) | ALDH1A1HCAR2 | |
| SCHEMBL5454725 | 0.84 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL5459841 | 0.84 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL5465987 | 0.84 | ALDH1A1 (0.33) | ALDH1A1HCAR2 | |
| SCHEMBL5471690 | 0.84 | — | — | |
| SCHEMBL5454781 | 0.82 | L3MBTL1 (0.37) | ALDH1A1 | |
| SCHEMBL3434106 | 0.80 | ALDH1A1 (0.41) | ALDH1A1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007146086-A1 | CREATINE PRODRUGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070281996-A1 | Creatine prodrugs, compositions and uses thereof | XENOPORT, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281996-A1 | Creatine prodrugs, compositions and uses thereof | CKMT1A; CKMT1B, PYGM, TNNI3 | ALDH1A1 2245/4885HCAR2 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.